OPKO Health, Inc. (OPK) stock
Close on Nov 12, 2026Market cap $1.25BP/E –Yield –
OPKO Health, Inc. saw revenue fall 8.3% to $501.64M over the twelve months to Sep 30, 2026. Free cash flow was -$135.34M. At the latest close the market valued the company at $1.25B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.25B
- P/E ratio
- –
- Price to sales
- 2.48
- Price to book
- 1.12
- Dividend yield
- –
- Free cash flow yield
- -10.86%
Fundamentals
- Revenue
- $501.64M
- Net income
- -$148.06M
- EPS, diluted
- -$0.19
- Free cash flow
- -$135.34M
- Book value per share
- $1.50
- Diluted shares
- 746M
Trading
- Next earnings
- Feb 25, 2027 (estimated, after the close)
- Previous close
- $1.71
- Open
- $1.71
- Day's range
- $1.66 – $1.74
- Volume
- 2,547,004
- Average volume (20 days)
- 3,955,095
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 0.92
- 52-week range
- $0.98 – $1.86
- RSI (14 days)
- 53.4
- Volatility (1 year)
- 57.1%
- Relative volume
- 0.64×
- WACC
- 9.5%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2010, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | OPK | S&P 500 | Difference | OPK per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +21.0% | -2.7% | +23.7 pts | ||
| 3 months | +20.1% | -1.7% | +21.9 pts | ||
| Year to date | +32.5% | +11.9% | +20.6 pts | ||
| 1 year | +26.5% | +12.0% | +14.5 pts | ||
| 3 years | +32.5% | +78.2% | −45.6 pts | +9.8% | +21.2% |
| 5 years | -59.5% | +73.2% | −132.7 pts | -16.5% | +11.6% |
| 10 years | -82.3% | +309.6% | −392.0 pts | -15.9% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases OPKO Health filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About OPKO Health
Pharmaceutical Preparations
OPKO Health is a healthcare enterprise that operates primarily through two main business segments: diagnostics and pharmaceuticals. Within its diagnostics division, the company provides diagnostic laboratory testing services and diagnostic products. Through its pharmaceutical division, the business develops, manufactures, and distributes pharmaceutical treatments and therapeutic compounds, including Rayaldee. The organization delivers its healthcare products and laboratory services to a diverse customer base that includes individual patients, commercial healthcare insurers, institutional client payers, and government healthcare programs such as Medicare and Medicaid.
Company profile, executives and historyOPKO Health stock: common questions
What is OPKO Health's stock price?
OPK closed at $1.67 on Nov 12, 2026, down 2.34% on the day. Over the past 52 weeks it traded between $0.98 and $1.86.
What is OPKO Health's market cap?
OPKO Health was worth $1.25B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is OPK's P/E ratio?
OPKO Health lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.19), so it has no meaningful P/E ratio.
How much revenue does OPKO Health make?
OPKO Health reported revenue of $501.64M for the twelve months to Sep 30, 2026, down 8.3% from a year earlier.
Does OPKO Health pay a dividend?
No. OPKO Health has not paid a cash dividend over the last twelve months.
When does OPKO Health report earnings next?
OPKO Health is expected to report Q4 FY2026 results on Feb 25, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has OPK stock performed over the past year?
Including dividends, OPK returned +26.5% over the past year, against +12.0% for the S&P 500.
How many OPK shares are sold short?
33M shares were sold short at the latest FINRA report, 7.80% of the float, or 9.2 days of average trading volume.
Who are OPKO Health's competitors?
Companies most similar to OPKO Health by business, industry and size include TLX, MNKD, AAPG, HROW, HCM.
See a number that looks wrong?